Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01735968 · ClinicalTrials.gov registry record · Phase 1
A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT01735968 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 56 participants.
The verdict
NCT01735968, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to determine a maximum tolerated dose and/or recommended phase 2 dose of a combination of imatinib and BYL719 in the treatment of 3rd line GIST patients.
Interventions
- DRUG ST571 + BYL719
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2013-02-27 |
| Est. Completion | 2018-10-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01735968
The ClinicalTrials.gov registry entry for NCT01735968 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ST571 + BYL719 is the first listed.
NCT01735968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01735968 about?
NCT01735968 is a clinical study titled "A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients". The purpose of this study is to determine a maximum tolerated dose and/or recommended phase 2 dose of a combination of imatinib and BYL719 in the treatment of 3rd line GIST patients.
What is the current status of trial NCT01735968?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2013-02-27. Estimated completion is 2018-10-19.
What interventions are being tested in trial NCT01735968?
The interventions under investigation include: ST571 + BYL719 (DRUG).
Who is sponsoring clinical trial NCT01735968?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.